Author(s): Shewach DS, Lawrence TS
Abstract Share this page
Abstract Gemcitabine is a novel nucleoside analog that has shown clinical activity in a variety of solid tumors. The use of gemcitabine in combination with radiation was investigated in vitro using HT-29 colon carcinoma cells. Gemcitabine was demonstrated to be a potent radiosensitizer even at noncytotoxic concentrations. Increasing the concentration of gemcitabine and/or the duration of exposure increased the radiosensitization of cells. Biochemical studies indicated that a reduction in the dATP pool was the most likely mechanism of radiosensitization by gemcitabine. This effect is of great clinical importance and should be investigated in vivo.
This article was published in Semin Oncol
and referenced in Journal of Carcinogenesis & Mutagenesis